Dynavax将以1200万美元收购疫苗生产商 周一，Dynavax生物技术公司宣布，计划以1200万美元的现金从Crucell公司手中收购德国疫苗生产商Rhein Biotech GmbH。 通过这次收购，加州伯克利的疫苗生产商Dynavax 将为其临床项目获得拥有欧洲认证的疫苗生产工厂，并控制乙型肝炎表面抗原以及其他潜在的抗原的生产，以支持其临床试验项目和商业项目。 Rhein Biotech GmbH 是Rhein Biotech AG的一部分，Rhein Biotech AG拥有其93%的股份。荷兰生物技术厂商Crucell NV最近购买了Berna。Dynavax和Berna有一个约定，为使用其乙肝疫苗的人提供乙型肝炎表面抗原。 Dynavax的CEO，Dino Dina在一份声明中说，收购Rhein Biotech，以加速公司拥有多种疫苗的特许权，成为乙肝抗原供应和产品生产以及其他项目的独立户，产生较好的投资回报率。 这项收购有望在六月完成。交易完成后，Dynavax和Berna之间的许可协议将完成，Berna将不再对Heplisav拥有商业权利。Dynavax研发乙肝病毒。Dynavax希望能够从Rhein的工业服务项目中获益，从项目合并中节约成本，与Berna的合作伙伴一起节省开支，来弥补近期收购Rhein Biotech带来的额外的开支。 Dynavax buys vaccine maker for $12M East Bay Business Times - 4:09 PM PST Monday Dynavax Technologies Corp. plans to acquire German vaccine maker Rhein Biotech Gmbh from Crucell NV for about $12 million in cash, the company announced Monday. The deal gives Berkeley-based vaccine maker Dynavax (NASDAQ: DVAX) a European Union-certified vaccine manufacturing plant, along with control over the production of hepatitis B surface antigen and potentially other antigens to support its clinical and commercial programs. Rhein Biotech GmbH is part of Rhein Biotech AG, which is 93 percent-owned by Berna Biotech AG. Dutch biotech firm Crucell NV recently bought Berna. Dynavax had an agreement with Berna for the supply of hepatitis B surface antigen for use with its hepatitis B vaccine. Dynavax CEO Dino Dina said in a statement that the acquisition of Rhein Biotech is designed to accelerate the company's strategy of building a diversified vaccine franchise, to provide independent ownership of antigen supply and product manufacturing for hepatitis B and other programs and to generate a "significant return on investment." The acquisition is expected to close by June. After the deal closes, the licensing agreement between Dynavax and Berna will end and Berna will no longer have an option to commercialize Heplisav. Dynavax's investigational hepatitis B vaccine. Dynavax expects that revenue from Rhein's industrial services business, cost savings from the combined business and the elimination of expenses associated with its Berna partnership will offset additional operating expenses related to Rhein Biotech in the near term From：Business Times http://www.bizjournals.com/eastbay/stories/2006/03/27/daily8.html 2006-03-28 目前Dynavax的治疗性乙肝疫苗正在做一期临床试验． 荷兰生物技术厂商Crucell是全球第六大疫苗供应商，Crucell公司出售Rhein Biotech GmbH工厂给Dynavax之后，与台湾國光生物科技股份有限公司宣布策略联盟，签订技术授权，國光生物将为Crucell代工量产，之前Crucell也曾对韩国Genexine技术授权，帮助Genexine研发和生产基因重组治疗性乙肝疫苗． www.dynavax.com www.crucell.com/Products-Hepavax-Gene www.adimmune.com.tw www.genexine.com http://www.hbvhbv.com/forum/dispbbs.asp?BoardID=13&replyID=148816&id=148816
[此贴子已经被作者于2007-5-31 22:19:43编辑过] | 
发表于 2006-12-20 08:54
